甘草酸二铵对慢活肝的疗效及免疫调节作用

甘草酸二铵是治疗肝炎的新药。本文采用甘草酸二铵对28例慢性活动性肝炎患者进行了治疗，疗程1个月，总有效率为93％与对照组（71％）相比差别有显著性（P＜0.05），和强力宁治疗组（95％）相比差别无显著性（P＞0.05）。在治疗同时，对单核吞噬细胞的吞噬功能、各类免疫球蛋白含量及T淋巴细胞亚群的变化进行了测定．结果甘草酸二铵组IgM水平治疗后比治疗前显著降低（P＜0.05），单核细胞吞噬率明显增高（P＜0.05），CD4细胞明显增高、CD8细胞明显降低，CD4／CD8的比值增高（P＜0.05）。提示甘草酸二铵对慢性活动性肝炎有明显的治疗作用，且可增强机体细胞免疫功能。     

促肝细胞生长素联合甘利欣治疗儿童急性乙型病毒性肝炎

目的观察促肝细胞生长素（HGF）联合甘利欣治疗小儿急性乙型病毒性肝炎（乙肝）的效果。方法180例患儿分成治疗组和对照组,各90例。两组均给予维生素C、肌苷、门冬氨酸钾镁、能量合剂。治疗组给予促肝细胞生长素20～60mg及甘利欣注射液50～100mg各加入10%GS250ml静滴,qd,15～30d为一疗程。对照组给予强力宁20～60ml及复方丹参注射液10～20ml各加入10%葡萄糖250ml静滴,qd,15～30d为一疗程,两组患儿均治疗2个疗程。结果治疗组显效63例,有效22例,无效5例,总有效率94.4%;对照组显效48例,有效27例,无效15例,总有效率83.3%;治疗组肝功能指标改善优于对照组,P均〈0.05。结论治疗组疗效明显优于对照组,促肝细胞生长素联合甘利欣治疗小儿急性乙肝疗效满意。     

复方甘草酸苷联合枸地氯雷他定治疗慢性特发性荨麻疹的临床研究

目的探讨复方甘草酸苷片联合枸地氯雷他定片治疗慢性特发性荨麻疹的临床疗效。方法选取2015年1月—2016年3月赤峰市医院皮肤科收治的慢性特发性荨麻疹患者124例,随机分为对照组和治疗组,每组各62例。对照组口服枸地氯雷他定片,1片/次,1次/d。治疗组在对照组基础上餐后口服复方甘草酸苷片,50 mg/次,3次/d。两组患者均连续治疗28 d。观察两组的临床疗效,比较两组的症状评分、细胞因子和抗体免疫球蛋白E(IgE)。结果治疗后,对照组和治疗组的总有效率分别为75.81%、91.94%,两组比较差异有统计学意义(P0.05)。治疗后,两组瘙痒程度、风团数量、风团直径、持续时间、发作次数、总评分均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组白细胞介素-2(IL-2)、白细胞介素-12(IL-12)、γ-干扰素(IFN-γ)水平显著升高,而白细胞介素-4(IL-4)、白细胞介素-8(IL-8)、IgE水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论复方甘草酸苷片联合枸地氯雷他定片治疗慢性特发性荨麻疹具有较好的临床疗效,能改善临床症状,升高IL-2、IL-12、IFN-γ水平,降低IL-4、IL-8、IgE水平,具有一定的临床推广应用价值。     

甘草甜素片联合腺苷蛋氨酸治疗肝内胆汁淤积性肝炎的疗效观察

目的探讨甘草甜素片联合注射用丁二磺酸腺苷蛋氨酸治疗肝内胆汁淤积性肝炎的临床疗效。方法选取2015年1月—2017年1月陕西省人民医院收治的肝内胆汁淤积性肝炎患者64例作为研究对象,所有患者随机分为对照组和治疗组,每组各32例。对照组静脉滴注注射用丁二磺酸腺苷蛋氨酸,1.0 g加入到15%葡萄糖溶液250 m L中,1次/d。治疗组在对照组基础上口服甘草甜素片,150 mg/次,2次/d。两组患者均连续治疗4周。观察两组的临床疗效,比较两组的症状改善和肝功能情况。结果治疗后,对照组和治疗组的总有效率分别为78.1%、96.9%,两组比较差异有统计学意义(P0.05)。治疗后,两组乏力、恶心呕吐、腹胀、灰白便、皮肤瘙痒的比例均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组丙氨酸氨基转移酶(ALT)、血清总胆红素(TBIL)、γ-谷氨酰转移酶(γ-GT)、碱性磷酸酶(ALP)、总胆汁酸(TBA)水平均明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论甘草甜素片联合注射用丁二磺酸腺苷蛋氨酸治疗肝内胆汁淤积性肝炎具有较好的临床疗效,可改善临床症状和肝功能指标,具有一定的临床推广应用价值。     

复方甘草酸苷联合阿维A治疗泛发性脓疱型银屑病临床分析

目的观察复方甘草酸苷联合阿维A治疗泛发性脓疱型银屑病的临床疗效。方法将64例泛发性脓疱型银屑病患者随机分成两组,各32例。治疗组静脉滴注复方甘草酸苷同时口服阿维A,对照组仅口服阿维A,疗程2个月。比较两组体温下降所需时间、无新发脓疱所需时间、皮损完全消退所需时间、平均住院时间、总有效率。结果治疗组体温下降所需时间为（4.26±1.32）d,无新发脓疱所需时间为（4.57±1.41）d,皮损完全消退所需时间为（18.74±3.43）d,平均住院时间为（21.76±3.78）d;对照组分别为（7.64±1.56）d、（7.66±1.62）d、（28.17±5.38）d、（32.42±5.61）d,两组比较差异均有统计学意义（均P〈0.05）。治疗组总有效率为84.38%,对照组为59.38%,治疗组的总有效率明显高于对照组（χ2=4.95,P〈0.05）。结论复方甘草酸苷联合阿维A治疗泛发性脓疱型银屑病疗效明显优于单用阿维A,并且起效快,不良反应少,值得临床推广。     

恩替卡韦联合复方甘草酸苷治疗48例肝癌患者．的疗效观察

目的探讨恩替卡韦联合复方甘草酸苷治疗原发性肝癌的临床治疗效果。方法选取2009年6月～2012年5月在我院消化内科住院的肝癌患者48例,随机分为试验组和对照组各24例,两组均行TACE治疗,同时均在术后1周予常规保肝治疗,其中试验组在术前1周予恩替卡韦联合复方甘草酸苷治疗,比较两组患者治疗前后ALT、AST、TBil、HBV—DNA的变化情况。结果两组术后出现不同程度肝功能损伤,术后1周,两组实验室检查表现为ALT、AST、TBil均较术前明显升高,差异有统计学意义（P〈0．05）。但试验组ALT、AST、TBil升高程度均低于对照组,差异有统计学意义（P〈0．05）。术后2周,试验组AST、TBil、HBV—DNA均较术前明最降低,且试验组明显低于对照组．差异有统计学意义（P〈0．05）。但ALT术后2周与术前比较未见明显差异,对照组HBV—DNA水平治疗前后也变化不明显。结论恩替卡韦联合复方甘草酸苷治疗原发性肝癌疗效确切,可以明显改善患者的肝功能．值得广泛推广和应用。     

Role of Glucocorticoid in the Development of Glycyrrhizin-Induced Hypertension

Role of alterations of corticosterone metabolism in the expression of the mineralocorticoid activity of glycyrrhizin was explored in rats. While the mineralocorticoid actions of oral glycyrrhizin were not observed in bilaterally adrenalectomized rats and dexamethasone treated rats, the mineralocorticoid actions of glycyrrhizin were fully expressed in bilaterally adrenalectomized rats supplemented with physiological doses of corticosterone. Similar mineralocorticoid actions were observed in rats given glycyrrhizin, deoxycorticosterone and pharmacological doses of corticosterone. Although increases in mean blood pressure were suppressed only by concurrent administration of spironolactone to glycyrrhizin- and deoxycorticosterone-treated rats, increases in mean blood pressure were attenuated by both the glucocorticoid antagonist RU 38486 and spironolactone in pharmacological doses of corticosterone administered rats. Pressor responses to norepinephrine and angiotensin II infusions in rats given deoxycorticosterone and pharmacological doses of corticosterone were significantly higher than in glycyrrhizin-treated rats. These results confirmed the functional significance of 11–beta-hydroxysteroid dehydrogenase in expression of the mineralocorticoid activity of glycyrrhizin.     

Survey of Glycyrrhizae Radix resources in Mongolia: chemical assessment of the underground part of Glycyrrhiza uralensis and comparison with Chinese Glycyrrhizea Radix

In order to reveal the chemical characteristics of Glycyrrhiza uralensis growing in Mongolia and to clarify whether it can be the source of Glycyrrhizae Radix used in Japan, eight major bioactive constituents in the underground parts of G. uralensis collected in Mongolia were quantitatively analyzed and compared with Glycyrrhizae Radix produced in China. Most of the 15 samples from eastern, southern and western parts of Mongolia contained 26.95–58.55 mg/g of glycyrrhizin, exceeding the criterion (25 mg/g) assigned in the Japanese Pharmacopoeia. The sample collected in Tamsagiyn hooly, Dornod province, in eastern Mongolia was of the highest content 58.55 mg/g. The contents of three flavanone constituents (liquiritin apioside, liquiritin and liquiritigenin) and three chalcones (isoliquiritin apioside, isoliquiritin and isoliquiritigenin) varied significantly according to collection places; the subtotal of the three flavanones ranged from 3.00 to 26.35 mg/g, and the subtotal of the three chalcones ranged from 1.13 to 10.50 mg/g. The content of glycyrrhizin and subtotal contents of flavanones and chalcones in the underground parts of G. uralensis from Mongolia were obviously lower than wild samples, but higher than cultivated samples derived from the same species produced in China. Glycycoumarin, a species-specific constituent of G. uralensis, was detected in all Mongolian samples. Its contents in samples from eastern Mongolia, Sergelen and Tamsagiyn hooly of Dornod province were very high and were compatible with Tohoku-kanzo derived from wild Chinese G. uralensis. The present study suggested that Mongolian G. uralensis could be a source of Glycyrrhizae Radix, mostly of Japanese Pharmacopoeia grade. However, the producing area should be taken into consideration to ensure relatively high quality. In addition, planned use and promotion of cultivation must be advocated to avoid confronting Mongolian Glycyrrhiza with the same threat as its congener in China. Our study sheds some light on selecting cultivation areas and superior strains, which are important tasks to promote cultivation.     

Si-Ni-San, a traditional Chinese prescription, and its active ingredient glycyrrhizin ameliorate experimental colitis through regulating cytokine balance

Si-Ni-San, a traditional Chinese medicinal formula, exerts an important function in the treatment of inflammatory bowel diseases based upon thousands of years of clinical practice, but the underlying mechanism is still unclear. In this study, we investigated the therapeutic potential of Si-Ni-San and its ingredient glycyrrhizin in trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis in mice, a well-characterized murine model for Crohn's disease. Si-Ni-San and glycyrrhizin significantly ameliorated TNBS-induced colitis with reduced mortality and recovery of body weights. In addition, Si-Ni-San and glycyrrhizin dose-dependently decreased macroscopic inflammation scores, microscopic histoligical scores, and myeloperoxidase activity. Furthermore, Si-Ni-San and glycyrrhizin caused a decrease in pro-inflammatory cytokines including IFN-γ, IL-12, TNF-α and IL-17 and an increase in regulatory cytokine IL-10 in colon of the mice. It should be noticed the therapeutic effect of Si-Ni-San at 450 mg/kg was much better than that of its contained content of glycyrrhizin at 10 mg/kg. In conclusion, Si-Ni-San and glycyrrhizin significantly ameliorated TNBS-induced colitis in mice through regulating pro- and anti-inflammtory cytokine production.     

复方甘草酸苷治疗慢性湿疹的疗效观察

目的探讨复方氟米松软膏治疗慢性湿疹的疗效。方法我院2008年9月～2009年5月诊治的72例慢性湿疹患者分为两组,对照组36例采用咪唑斯汀片、复方氟米松软膏治疗,治疗组36例在对照组的基础上加用复方甘草酸苷片治疗,两组疗程均为4周。结果治疗组与对照组的总有效率分别为94．4％、77．8％,组间有显著性差异（χ2=4．1807,P〈0．05）;治疗组与对照组的不良反应发生率分别为8．3％、5．6％,组间无显著性差异（χ2=0．2149,P〉0．05）。结论复方甘草酸苷治疗慢性湿疹可获得满意疗效,且安全性好,值得临床推广应用。